They show that giving the leukemia drugs nilotinib or
bafetinib to fly larvae with the equivalent of Fragile X prevented the wild overgrowth of neuron endings associated with the disorder.
Its oncology pipeline includes three programmes in clinical development for cancer indications: INNO-206, tamibarotene and
bafetinib.
Net proceeds from the proposed offering will be used by the company to fund the clinical development of its drug candidates INNO-206,
bafetinib and tamibarotene, for general corporate purposes, as working capital, capital expenditures, research and development expenditures and other commercial expenditures.
That includes two trials for
bafetinib, a possible treatment for people with certain advanced forms of leukemia.
15 January 2010 - US-based biopharmaceutical company CytRx Corporation (NASDAQ:CYTR) said on Wednesday it plans to initiate a Phase II proof-of-concept clinical trial to evaluate the efficacy and safety of bafetinib (formerly known as INNO-406) in patients with high-risk B-cell chronic lymphocytic leukemia (B-CLL).
Bafetinib is a potent, orally available, rationally designed, dual Bcr-Abl and Lyn-kinase inhibitor, which is currently being planned as a third-line treatment for patients with chronic myeloid leukemia (CML) or certain forms of acute myeloid leukemia (AML) that are refractory or intolerant of other approved treatments.
In the planned Phase II trial, approximately 20 patients who have failed treatment with first-line agents will be administered daily oral doses of bafetinib. Patients will be monitored for clinical response, time to disease progression and cancer progression-free survival.